References
- Caldwell DR, Salisbury CR, Guzek JP. Effects of topical betaxolol in ocular hypertensive patients. Arch Ophthalmol 1984;102:539–540
- Feghali JG, Kaufman PL. Decreased intraocular pressure in the hypertensive human eye with betaxolol, a beta 1-adrenergic antagonist. Am J Ophthalmol 1985;100:777–782
- FDA Medical Review of Lumigan (Bimatoprost), Application 21-275, Protocol 192024-001. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21275_Lumigan%200.03%20percent%20Opthalmis%20Solution_medr_P2.pdf [last accessed 28 Jul 2014]
- Laibovitz RA, VanDenburgh AM, Felix C, David R, Batoosingh A, Rosenthal A, Cheetham J. Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma management. Arch Ophthalmol 2001;119:994–1000
- FDA Medical Review of Lumigan (Bimatoprost), Application 21-275, Protocol 192024-003. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21275_Lumigan%200.03%20percent%20Opthalmis%20Solution_medr_P2.pdf [last accessed 28 Jul 2014]
- FDA Medical Review of Lumigan (Bimatoprost), Application 21-275, Protocol 192024-004. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21275_Lumigan%200.03%20percent%20Opthalmis%20Solution_medr_P2.pdf [last accessed 28 Jul 2014]
- Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995;113:1514–1517
- Derick RJ, Robin AL, Walters TR, Barnebey HS, Choplin N, Schuman J, et al. Brimonidine tartrate: a one-month dose response study. Ophthalmology 1997;104:131–136
- FDA Medical Review of Brinzolamide (Azopt), Application 20-816, Protocol C92-25. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20816_AZOPT_MEDR_P1.PDF [last accessed 28 Jul 2014]
- Lippa EA, Schuman JS, Higginbotham EJ, Kass MA, Weinreb RN, Skuta GL, et al. MK-507 versus sezolamide. Comparative efficacy of two topically active carbonic anhydrase inhibitors. Ophthalmology 1991;98:308–312
- Lippa EA, Carlson LE, Ehinger B, Eriksson LO, Finnström K, Holmin C, et al. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol 1992;110:495–499
- Wilkerson M, Cyrlin M, Lippa EA, Esposito D, Deasy D, Panebianco D, et al. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol 1993;111:1343–1350
- Rácz P, Ruzsonyi MR, Nagy ZT, Bito LZ. Maintained intraocular pressure reduction with once-a-day application of a new prostaglandin F2 alpha analogue (PhXA41). An in-hospital, placebo-controlled study. Arch Ophthalmol 1993;111:657–661
- Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993;100:1297–1304
- Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 1993;111:1351–1358
- Alm A, Villumsen J, Törnquist P, Mandahl A, Airaksinen J, Tuulonen A, et al. Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study. Ophthalmology 1993;100:1312–1316
- Nagasubramanian S, Sheth GP, Hitchings RA, Stjernschantz J. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens. Ophthalmology 1993;100:1305–1311
- Villumsen J, Alm A. PhXA34 – a prostaglandin F2 alpha analogue. Effect on intraocular pressure in patients with ocular hypertension. Br J Ophthalmol 1992;76:214–217
- Partamian LG, Kass MA, Gordon M. A dose-response study of the effect of levobunolol on ocular hypertension. Am J Ophthalmol 1983;95:229–232
- Bensinger RE, Keates EU, Gofman JD, Novack GD, Levobunolol DE. A three-month efficacy study in the treatment of glaucoma and ocular hypertension. Arch Ophthalmol 1985;103:375–378
- Zimmerman TJ, Kaufman HE. Timolol: dose response and duration of action. Arch Ophthalmol 1977;95:605–607
- FDA Medical Review of Travoprost (Travatan), Application 21-257, Protocol C-97-02. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21257_Travatan_medr_P1.pdf [last accessed 28 Jul 2014]
- FDA Medical Review of Unoprostone (Rescula), Application 21-214, Protocol C97-UIOS-003. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21214_Rescula_medr_P2.pdf [last accessed 28 Jul 2014]
- Kienle GS, Kiene H. The powerful placebo effect: fact or fiction? J Clin Epidemiol 1997;50:1311–1318
- Margo CE. The placebo effect. Surv Ophthalmol 1999;44:31–44
- Haour F. Mechanisms of the placebo effect and of conditioning. Neuroimmunomodulation 2005;12:195–200
- Stewart WC. Clinical practice of glaucoma. Thorofare: SLACK Inc.; 1990. pp 255–297